JungMin Choi MD , So-Ryoung Lee MD, PhD , Tae-Hoon Kim MD , Hee Tae Yu MD, PhD , Junbeom Park MD, PhD , Jin-Kyu Park MD, PhD , Ki-Woon Kang MD, PhD , Jaemin Shim MD, PhD , Jae-Sun Uhm MD, PhD , Jun Kim MD, PhD , Hyung Wook Park MD, PhD , Jin-Bae Kim MD , Young Soo Lee MD, PhD , Boyoung Joung MD, PhD , Eue-Keun Choi MD, PhD
{"title":"新诊断为心房颤动和既往诊断为心房颤动的亚洲患者的临床结局:来自 CODE-AF 登记的启示。","authors":"JungMin Choi MD , So-Ryoung Lee MD, PhD , Tae-Hoon Kim MD , Hee Tae Yu MD, PhD , Junbeom Park MD, PhD , Jin-Kyu Park MD, PhD , Ki-Woon Kang MD, PhD , Jaemin Shim MD, PhD , Jae-Sun Uhm MD, PhD , Jun Kim MD, PhD , Hyung Wook Park MD, PhD , Jin-Bae Kim MD , Young Soo Lee MD, PhD , Boyoung Joung MD, PhD , Eue-Keun Choi MD, PhD","doi":"10.1016/j.hrthm.2024.10.046","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Atrial fibrillation (AF) may have different clinical features in its early phase.</div></div><div><h3>Objective</h3><div>The purpose of this study was to compare the characteristics and clinical outcomes of early-phase AF with later-phase AF using a large multicenter prospective registry (CODE-AF [COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation]).</div></div><div><h3>Methods</h3><div>Patients enrolled between June 2016 and March 2021 were divided into 2 groups based on AF duration: (1) newly diagnosed (AF duration ≤90 days); and (2) previously diagnosed (AF duration >90 days). Baseline characteristics and clinical outcomes were compared.</div></div><div><h3>Results</h3><div>Among the 10,001 study participants (mean age 67.0 ± 14.5 years; 64% men), 22% were defined as newly diagnosed and 78% as previously diagnosed. Newly diagnosed patients had fewer comorbidities and more unhealthy social behaviors. Despite lower prescription rates of oral anticoagulant, direct oral anticoagulants were more frequently used. The newly diagnosed group also had a higher composite clinical outcome risk within 90 days (adjusted hazard ratio 1.81, 95% confidence interval 1.30–2.53, <em>P</em> <.001) and revealed a higher risk of all bleeding and heart failure admission within 90 days. No significant differences remained between the groups over 36-month follow-up.</div></div><div><h3>Conclusion</h3><div>Patients with early-stage AF were younger and had fewer comorbidities. Although there was a higher risk of heart failure admissions and minor bleeding, the risks of death, stroke, and major bleeding were not significantly increased. Structured monitoring and management during the initial months are essential to address these risks.</div></div>","PeriodicalId":12886,"journal":{"name":"Heart rhythm","volume":"22 2","pages":"Pages 424-431"},"PeriodicalIF":5.6000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical outcomes of Asian patients with newly diagnosed atrial fibrillation and previously diagnosed atrial fibrillation: Insights from the CODE-AF Registry\",\"authors\":\"JungMin Choi MD , So-Ryoung Lee MD, PhD , Tae-Hoon Kim MD , Hee Tae Yu MD, PhD , Junbeom Park MD, PhD , Jin-Kyu Park MD, PhD , Ki-Woon Kang MD, PhD , Jaemin Shim MD, PhD , Jae-Sun Uhm MD, PhD , Jun Kim MD, PhD , Hyung Wook Park MD, PhD , Jin-Bae Kim MD , Young Soo Lee MD, PhD , Boyoung Joung MD, PhD , Eue-Keun Choi MD, PhD\",\"doi\":\"10.1016/j.hrthm.2024.10.046\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Atrial fibrillation (AF) may have different clinical features in its early phase.</div></div><div><h3>Objective</h3><div>The purpose of this study was to compare the characteristics and clinical outcomes of early-phase AF with later-phase AF using a large multicenter prospective registry (CODE-AF [COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation]).</div></div><div><h3>Methods</h3><div>Patients enrolled between June 2016 and March 2021 were divided into 2 groups based on AF duration: (1) newly diagnosed (AF duration ≤90 days); and (2) previously diagnosed (AF duration >90 days). Baseline characteristics and clinical outcomes were compared.</div></div><div><h3>Results</h3><div>Among the 10,001 study participants (mean age 67.0 ± 14.5 years; 64% men), 22% were defined as newly diagnosed and 78% as previously diagnosed. Newly diagnosed patients had fewer comorbidities and more unhealthy social behaviors. Despite lower prescription rates of oral anticoagulant, direct oral anticoagulants were more frequently used. The newly diagnosed group also had a higher composite clinical outcome risk within 90 days (adjusted hazard ratio 1.81, 95% confidence interval 1.30–2.53, <em>P</em> <.001) and revealed a higher risk of all bleeding and heart failure admission within 90 days. No significant differences remained between the groups over 36-month follow-up.</div></div><div><h3>Conclusion</h3><div>Patients with early-stage AF were younger and had fewer comorbidities. Although there was a higher risk of heart failure admissions and minor bleeding, the risks of death, stroke, and major bleeding were not significantly increased. Structured monitoring and management during the initial months are essential to address these risks.</div></div>\",\"PeriodicalId\":12886,\"journal\":{\"name\":\"Heart rhythm\",\"volume\":\"22 2\",\"pages\":\"Pages 424-431\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Heart rhythm\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1547527124035070\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart rhythm","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1547527124035070","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Clinical outcomes of Asian patients with newly diagnosed atrial fibrillation and previously diagnosed atrial fibrillation: Insights from the CODE-AF Registry
Background
Atrial fibrillation (AF) may have different clinical features in its early phase.
Objective
The purpose of this study was to compare the characteristics and clinical outcomes of early-phase AF with later-phase AF using a large multicenter prospective registry (CODE-AF [COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation]).
Methods
Patients enrolled between June 2016 and March 2021 were divided into 2 groups based on AF duration: (1) newly diagnosed (AF duration ≤90 days); and (2) previously diagnosed (AF duration >90 days). Baseline characteristics and clinical outcomes were compared.
Results
Among the 10,001 study participants (mean age 67.0 ± 14.5 years; 64% men), 22% were defined as newly diagnosed and 78% as previously diagnosed. Newly diagnosed patients had fewer comorbidities and more unhealthy social behaviors. Despite lower prescription rates of oral anticoagulant, direct oral anticoagulants were more frequently used. The newly diagnosed group also had a higher composite clinical outcome risk within 90 days (adjusted hazard ratio 1.81, 95% confidence interval 1.30–2.53, P <.001) and revealed a higher risk of all bleeding and heart failure admission within 90 days. No significant differences remained between the groups over 36-month follow-up.
Conclusion
Patients with early-stage AF were younger and had fewer comorbidities. Although there was a higher risk of heart failure admissions and minor bleeding, the risks of death, stroke, and major bleeding were not significantly increased. Structured monitoring and management during the initial months are essential to address these risks.
期刊介绍:
HeartRhythm, the official Journal of the Heart Rhythm Society and the Cardiac Electrophysiology Society, is a unique journal for fundamental discovery and clinical applicability.
HeartRhythm integrates the entire cardiac electrophysiology (EP) community from basic and clinical academic researchers, private practitioners, engineers, allied professionals, industry, and trainees, all of whom are vital and interdependent members of our EP community.
The Heart Rhythm Society is the international leader in science, education, and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education, and optimal health care policies and standards.